<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1602210522
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Vyndamax
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TAFAMIDIS
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        61
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, soft
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        44267.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="CATALENT PHARMA SOLUTIONS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            CATALENT PHARMA SOLUTIONS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            PFIZER INC
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N07XX08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>VYNDAMAX (tafamidis) is prescription medicine used to treat adults with cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) to reduce death and hospitalization related to heart problems.</p><p>It is not known if VYNDAMAX is safe and effective in children.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><em>&nbsp;</em></p><p><strong>Do not take Vyndamax</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to {tafamidis} or any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor or pharmacist before Taking Vyndamax if you:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have liver problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are pregnant or plan to become pregnant. VYNDAMAX may harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with VYNDAMAX.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are breastfeeding or plan to breastfeed. It is not known if VYNDAMAX passes into your breast milk. You should not breastfeed during treatment with VYNDAMAX. Talk to your healthcare provider about the best way to feed your baby during treatment with VYNDAMAX.</p><p>&nbsp;</p><p>Tell your healthcare provider about all the medicines you take including any prescription or over‑the‑counter medicines, vitamins, and herbal supplements.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>The safety and effectiveness of VYNDAMAX has not been established in pediatric patients.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and VYNDAMAX</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>You should inform your doctor or pharmacist if you are taking any of the following:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anti-cancer medicines (e.g. methotrexate, imatinib)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; statins (e.g. rosuvastatin)</p><p>&nbsp;</p><p><strong>Pregnancy and&nbsp; breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; VYNDAMAX may harm your unborn baby.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is not known if VYNDAMAX passes into your breast milk. You should not breastfeed during treatment with VYNDAMAX. Talk to your healthcare provider about the best way to feed your baby during treatment with VYNDAMAX.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>No studies on the effects of Vyndamax on the ability to drive or use machines have been performed.</p><p>&nbsp;</p><p><strong>VYNDAMAX contains sorbitol</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take<strong> </strong>VYNDAMAX exactly as your healthcare provider tells you to.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take VYNDAMAX capsule(s) 1 time a day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; VYNDAMAX capsule should be swallowed whole and not crushed or cut.</p><p>&nbsp;</p><p><strong>If you take more Vyndamax than you should</strong></p><p>You should not take more capsules than your doctor tells you to. If you take more capsules than you have been told to take, contact your doctor.</p><p><em>&nbsp;</em></p><p><strong>If you forget to take Vyndamax</strong></p><p>If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and take the next dose at your regularly scheduled time. Do not take 2 doses at the same time.</p><p>&nbsp;</p><p><strong>If you stop taking Vyndamax</strong></p><p>Do not stop taking Vyndamax without first speaking to your doctor</p><p><strong>&nbsp;</strong></p><p>If you have any further questions on the use of this medicine, ask your doctor,or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>&nbsp;</strong></p><p>If you get any side effects, talk to your doctor or ,pharmacist. This includes any possible side effects not listed in this leaflet.</p><p>&nbsp;</p><p>There were no known side effects that happenedduring treatment with VYNDAMAX in people with cardiomyopathy of transthyretin-mediated amyloidosis.</p><p>&nbsp;</p><p><strong>Reporting side effects </strong></p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor, pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system . By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Center ( NPC )</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the reach and sight of children</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the label. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Don&#39;t store above 30&deg;C.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Active ingredient</strong>: Tafamidis</p><p><strong>Inactive ingredients:</strong></p><p>Polyethylene Glycol 400</p><p>Polysorbate 20<br />Povidone<br />Butylated Hydroxytoluene<br /><br />Gelatin Shell&nbsp; Ingredients:<br />Gelatin<br />Sorbitol Special-Glycerin Blend<br />Iron Oxide, Red<br /><br />Gelatin Shell Printing Ingredients:<br />Ink, White Opacode</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Reddish brown, opaque, oblong capsule, printed with “VYN 61” in white.

The carton contain 3 Aluminum Foil blister cards. Each blister card contains 10 capsules. (30 capsules total).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Pfizer Inc.</p><p>66 Hudson Boulevard East , New York, NY 10001, USA</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>Catalent Pharma Solutions, LLC, Saint Petersburg, FL, USA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                October 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">فينداماكس (تافامايدس) هو دواء يصرف بوصفة طبية ويستخدم لعلاج البالغين المصابين باعتلال عضلة القلب الناتج عن الداء النشواني من النمط البري أو الوراثي المتواسط بالبروتين الناقل ترانسثيريتين (ATTR-CM)، وذلك لتقليل حالات الوفاة والدخول إلى المستشفى المتعلقة بمشكلات القلب.</p><p dir="RTL">ليس معروفًا إذا ما كان فينداماكس آمنًا وفعالًا للاستخدام مع الأطفال أم لا.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>موانع استعمال فينداماكس</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه { تافامايدس} أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم ٦).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال فينداماكس </strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل تناول فينداماكس إذا:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من مشكلات في الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنتِ حاملًا أو تخططين للحمل. قد يسبب فينداماكس ضررًا لجنينكِ. أخبري مقدم الرعاية الصحية الخاص بكِ على الفور إذا أصبحتِ حاملًا أو كنتِ تعتقدين أنكِ ربما تكونين حاملًا أثناء العلاج بفينداماكس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنتِ تُرضعين رضاعة طبيعية أو تخططين لذلك. ليس معروفًا إذا ما كان فينداماكس يمر إلى لبن الثدي لديكِ أم لا. ينبغي ألا تُرضعي طفلكِ طبيعيًا أثناء العلاج بفينداماكس. تحدثي إلى مُقدم الرعاية الصحية الخاص بكِ بشأن أفضل طريقة لإطعام طفلكِ أثناء العلاج بفينداماكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر مقدم الرعاية الصحية الخاص بك بجميع الأدوية التي تتناولها، بما في ذلك أي أدوية، وفيتامينات، ومكملات عشبية تُصرف بوصفة طبية أو بدونها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لم تُثبت سلامة وفعالية فينداماكس مع المرضى من الأطفال.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ال</strong><strong>تداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي أن تبلغ طبيبك أو الصيدلي إذا كنت تتناول أيًا من التالي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة للسرطان (مثل ميثوتريكسات، إيماتينيب)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الستاتينات (مثل روزوفاستاتين)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنتِ حاملًا أو تُرضعين رضاعة طبيعية، أو تعتقدين أنكِ ربما تكونين حاملًا، أو تخططين للإنجاب فاستشيري طبيبكِ أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يسبب فينداماكس ضررًا لجنينكِ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ليس معروفًا إذا ما كان فينداماكس يمر إلى لبن الثدي لديكِ أم لا. ينبغي ألا تُرضعي طفلكِ طبيعيًا أثناء العلاج بفينداماكس. تحدثي إلى مُقدم الرعاية الصحية الخاص بكِ بشأن أفضل طريقة لإطعام طفلكِ أثناء العلاج فينداماكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير فينداماكس على القيادة واستخدام الآلات</strong></p><p dir="RTL">لم تُجر أي دراسات عن تأثيرات فينداماكس على القدرة على القيادة أو استخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات فينداماكس</strong></p><p dir="RTL">يحتوي فينداماكس على السوربيتول</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تناول<strong> </strong>فينداماكس كما يخبرك مقدم الرعاية الصحية الخاص بك بالضبط.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول كبسولة (كبسولات) فينداماكس مرة واحدة يوميًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي ابتلاع كبسولة فينداماكس كاملةً وعدم سحقها أو تقسيمها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من فينداماكس</strong></p><p dir="RTL">ينبغي ألا تتناول عدد كبسولات أكثر مما وصفه لك طبيبك. إذا تناولت عدد كبسولات أكثر مما وُصف لك، فاتصل بطبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة فينداماكس</strong></p><p dir="RTL">إذا فاتتك إحدى الجرعات، فتناولها بمجرد أن تتذكرها. إذا كان موعد تناول جرعتك التالية وشيكًا، فتخط الجرعة الفائتة وتناول الجرعة التالية في موعدك المحدد المعتاد. لا تتناول جرعتين في نفس الوقت.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول فينداماكس</strong></p><p dir="RTL">لا تتوقف عن تناول فينداماكس دون التحدث إلى طبيبك أولًا</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية بشأن استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، يمكن أن يسبب هذا الدواء أعراضًا جانبية، غير أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبت بأي أعراض جانبية، فتحدث إلى طبيبك أو الصيدلي. يتضمن هذا أي أعراض جانبية محتملة غير مدرجة في هذه النشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لم تحدث أعراض جانبية معروفة أثناء العلاج بفينداماكس لدى الأشخاص المصابين باعتلال عضلة القلب الناتج عن الداء النشواني المتواسط بالبروتين الناقل ترانسثيريتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية </strong></p><p dir="RTL">إذا أصبت بأي أعراض جانبية، فتحدث إلى طبيبك أو الصيدلي. يتضمن هذا أي أعراض جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الأعراض الجانبية مباشرةً عبر نظام الإبلاغ القومي. بالإبلاغ عن الأعراض الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>المركز الوطني للتيقظ الدوائي:</strong></p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp; </em>مركز الاتصال الموحد: ١٩٩٩٩</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp; </em><em>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</em></p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدًا عن متناول ومرأى الأطفال</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على الملصق يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحفظ في درجة حرارة لا تزيد عن ٣٠ درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المكون الفعال</strong>: تافامايدس</p><p dir="RTL"><strong>المكونات غير الفعالة:</strong><br />بولي إيثيلين جليكول ٤٠٠<br />بولي سوربات ٢٠<br />بوفيدون<br />هيدروكسي تولوين بوتيلي،<br /><br />مواد الكبسولة الجلاتينية:<br />جلاتين<br />خليط سوربيتول مع جليسين<br />أكسيد الحديد<br /><br />مواد حبر الطباعة على الكبسولة الجلاتينية:<br />حبر ابيض</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>كبسولات بنية محمرة، داكنة، مستطيلة الشكل ومطبوع عليها &quot;VYN 61&quot; باللون الأبيض.<br /><br />يحتوي الكرتون على ٣ أشرطة، وكل شريط يحتوي على ١٠ كبسولات (بمجموع ٣٠ كبسولة في العلبة).<br /><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق</strong></p><p dir="RTL">Pfizer Inc.<br />66Hudson Boulevard East, New York, NY 10001, USA</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المصنع:</strong><br />Catalent Pharma Solutions, LLC<br />Saint Petersburg, FL, USA</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            اكتوبر 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                VYNDAMAX 61 mg capsules, for oral administration
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                VYNDAMAX contain tafamidis as the active moiety, which is a selective stabilizer of transthyretin.

The chemical name of tafamidis is 2 (3,5 dichlorophenyl) 1,3 benzoxazole 6 carboxylic acid. The molecular formula is C14H7Cl2NO3, and the molecular weight is 308.12 g/mol. The structural formula is:

		






Tafamidis 61 mg soft gelatin capsule for oral use contains a white to pink colored suspension of tafamidis 61 mg. 

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Soft gelatin capsules.

reddish brown, opaque, oblong capsule, printed with “VYN 61” in white.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>VYNDAMAX is indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin‑mediated amyloidosis (ATTR‑CM) in adults to reduce cardiovascular mortality and cardiovascular‑related hospitalization.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The recommended dosage is VYNDAMAX 61 mg (one 61‑mg tafamidis capsule) orally once daily.</p><p>&nbsp;</p><p>VYNDAMAX is not substitutable on a per&nbsp;mg basis <em>[see section 5 Pharmacological Properties]</em>.</p><p><em>&nbsp;</em></p><p><em><u>Administration Instructions</u></em></p><p>&nbsp;</p><p>The capsules should be swallowed whole and not crushed or cut.</p><p>&nbsp;</p><p>If a dose is missed, instruct patients to take the dose as soon as remembered or to skip the missed dose and take the next dose at the regularly scheduled time. Do not double the dose.</p><p><strong>&nbsp;</strong></p><p><em><u>Special population</u></em></p><p><em><u>&nbsp;</u></em></p><p><strong><em>Pediatric Use</em></strong></p><p>&nbsp;</p><p>The safety and effectiveness of VYNDAMAX have not been established in pediatric patients.</p><p><em>&nbsp;</em></p><p><strong><em>Geriatric Use</em></strong></p><p>&nbsp;</p><p>No dosage adjustment is required for elderly patients (&ge;65 years) <em>[see section 5 Pharmacological Properties]</em>.<em> </em>Of the total number of patients in the clinical study (n=441), 90.5% were 65 and over, with a median age of 75 years.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Pregnant women and females of reproductive potential should be aware of the potential risk to a fetus. Females should inform their healthcare provider of a known or suspected pregnancy <em>[see section 4.6 Fertility, pregnancy and lactation]. </em></p><p>&nbsp;</p><p><u>Lactation</u></p><p>Females should not breastfeed during treatment with VYNDAMAX <em>[see section 4.6 Fertility, pregnancy and lactation]</em>.</p><p>&nbsp;</p><p>This medicinal product contains sorbitol.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>BCRP Substrates</strong></p><p>&nbsp;</p><p>Tafamidis inhibits breast cancer resistant protein (BCRP) in humans (see Clinical Pharmacology). Coadministration of tafamidis and drugs that are BCRP substrates may increase the exposure of substrates of this transporter (e.g., methotrexate, rosuvastatin, imatinib) and the risk of the substrate-related toxicities. Monitor for signs of BCRP substrate-related toxicities and modify dosage of the substrate if appropriate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy </strong></p><p><strong>&nbsp;</strong></p><p><u>Risk Summary</u></p><p>Based on findings from animal studies, VYNDAMAX may cause fetal harm when administered to a pregnant woman.&nbsp; However, limited available human data with VYNDAQEL use in pregnant women (at a dose of 20 mg per day) have not identified any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproductive studies, oral administration of tafamidis meglumine to pregnant rabbits during organogenesis resulted in adverse effects on development (embryofetal mortality, fetal body weight reduction and fetal malformation) at a dosage providing approximately 9 times the human exposure (AUC) at the maximum recommended human dose (MRHD) of VYNDAQEL (80&nbsp;mg), and increased incidence of fetal skeletal variation at a dosage providing equivalent human exposure (AUC) at the MRHD. Postnatal mortality, growth retardation, and impaired learning and memory were observed in offspring of pregnant rats administered tafamidis meglumine during gestation and lactation at a dosage approximately 2 times the MRHD based on body surface area (mg/m2) (see Data). Advise pregnant women of the potential risk to a fetus.</p><p>&nbsp;</p><p>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</p><p><u>&nbsp;</u></p><p><u>Data</u></p><p>Animal Data</p><p>In pregnant rats, oral administration of tafamidis meglumine (0, 15, 30, and 45&nbsp;mg/kg/day) throughout organogenesis resulted in decreased fetal body weights at &ge;30&nbsp;mg/kg/day (approximately 10 times the human exposure at the MRHD based on AUC). The no-observed-adverse-effect-level (NOAEL) for embryofetal development in rats was 15 mg/kg/day (approximately 7 times the human exposure at the MRHD based on AUC).</p><p>&nbsp;</p><p>In pregnant rabbits, oral administration of tafamidis meglumine (0, 0.5, 2, and 8&nbsp;mg/kg/day) throughout organogenesis resulted in increased embryofetal mortality, reduced fetal body weights, and an increased incidence of fetal malformations at 8 mg/kg/day (approximately 9 times the human exposure at the MRHD based on AUC), which was also maternally toxic. Increased incidences of fetal skeletal variations were observed at doses &ge;0.5&nbsp;mg/kg/day (approximately equivalent to the human exposure at the MRHD based on AUC).&nbsp;</p><p><u>&nbsp;</u></p><p>In the pre- and postnatal study, pregnant rats received oral administration of tafamidis meglumine at doses of 0, 5, 15, or 30&nbsp;mg/kg/day throughout pregnancy and lactation (Gestation Day 7 to Lactation Day 20). Decreased survival and body weights, delayed male sexual maturation and neurobehavioral effects (learning and memory impairment) were observed in the offspring of dams treated at 15&nbsp;mg/kg/day (approximately 2 times the MRHD on a mg/m<sup>2</sup> basis). The NOAEL for pre- and postnatal development in rats was 5 mg/kg/day (approximately equivalent to the MRHD on a mg/m<sup>2</sup> basis).</p><p><u>&nbsp;</u></p><p><strong>Lactation</strong></p><p><strong>&nbsp;</strong></p><p><u>Risk Summary</u></p><p>There are no available data on the presence of tafamidis in human milk, the effect on the breastfed infant, or the effect on milk production. Tafamidis is present in rat milk <em>(see Data)</em>. When a drug is present in animal milk, it is likely the drug will be present in human milk. Based on findings from animal studies which suggest the potential for serious adverse reactions in the breastfed infant, advise patients that breastfeeding is not recommended during treatment with VYNDAMAX.</p><p>&nbsp;</p><p><u>Data</u></p><p>Pregnant and lactating female rats were administered repeated daily oral doses of tafamidis meglumine (15&nbsp;mg/kg/day) followed by a single oral gavage dose of <sup>14</sup>C‑tafamidis meglumine on Lactation Day 4 or 12. Radioactivity was observed in milk by 1 hour post‑dose and increased thereafter. The ratio of the highest radioactivity associated with <sup>14</sup>C tafamidis meglumine in milk (8 hours post-dose) vs. plasma (1 hour post‑dose) was approximately 1.6 on Day 12, indicating tafamidis meglumine is transferred to milk after oral administration.</p><p>&nbsp;</p><p><strong>Females and Males of Reproductive Potential</strong></p><p><strong>&nbsp;</strong></p><p><u>Contraception</u></p><p>Females</p><p>Based on findings from animal studies, VYNDAMAX may cause fetal harm when administered to a pregnant woman. Consider pregnancy planning and prevention for females of reproductive potential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of VYNDAMAX on the ability to drive or use machines have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Clinical Trials Experience</strong></p><p>&nbsp;</p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p>&nbsp;</p><p>The data reflect exposure of 377 ATTR‑CM patients to 20&nbsp;mg or 80&nbsp;mg (administered as four 20‑mg capsules) of VYNDAQEL administered daily for an average of 24.5 months (ranging from 1 day to 111 months).</p><p>&nbsp;</p><p>Adverse events were assessed from ATTR‑CM clinical trials with VYNDAQEL, primarily a 30‑month placebo‑controlled trial <em>[see Clinical Studies]</em>. The frequency of adverse events in patients treated with VYNDAQEL 20&nbsp;mg (n=88) or 80&nbsp;mg (n=176; administered as four 20‑mg capsules) was similar to that with placebo (n=177).</p><p>&nbsp;</p><p>In the 30‑month placebo‑controlled trial, similar proportions of VYNDAQEL‑treated patients and placebo‑treated patients discontinued the study drug because of an adverse event: 12 (7%), 5 (6%), and 11 (6%) from the VYNDAQEL 80-mg, VYNDAQEL 20-mg, and placebo groups, respectively.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;</p><p><strong><u>Reporting of adverse reactions</u></strong></p><p>Reporting suspected adverse reactions after <u>marketing</u> authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions according to national pharmacovigilance center requirements.</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Center (NPC)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa<u> </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong> <strong>GCC states</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority </em></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is minimal clinical experience with overdose. During clinical trials, two patients accidentally ingested a single VYNDAQEL dose of 160&nbsp;mg without adverse events. The highest dose of tafamidis meglumine given to healthy volunteers in a clinical trial was 480&nbsp;mg as a single dose. There was one reported adverse event of mild hordeolum at this dose.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Mechanism of Action</strong></p><p>&nbsp;</p><p>Tafamidis is a selective stabilizer of TTR. Tafamidis binds to TTR at the thyroxine binding sites, stabilizing the tetramer and slowing dissociation into monomers, the rate‑limiting step in the amyloidogenic process.</p><p>&nbsp;</p><p><strong>Pharmacodynamics</strong></p><p>&nbsp;</p><p>A proprietary TTR stabilization assay was utilized as a pharmacodynamic marker and assessed the stability of the TTR tetramer ex&nbsp;vivo. The TTR stabilization assay quantifies immunoturbidimetric measurement of the stable TTR tetramer in plasma pre- and post‑treatment with 2‑day in vitro denaturation with urea. Using this proprietary assay, a dose‑dependent trend for greater TTR tetramer stabilization is observed for VYNDAQEL 80‑mg compared to VYNDAQEL 20‑mg. However, the clinical relevance of a higher TTR tetramer stabilization towards cardiovascular outcomes is not known.</p><p>&nbsp;</p><p>VYNDAQEL stabilized both the wild type TTR tetramer and the tetramers of 14 TTR variants tested clinically after once‑daily dosing. Tafamidis also stabilized the TTR tetramer for 25 variants tested ex vivo.</p><p>&nbsp;</p><p>VYNDAQEL and VYNDAMAX may decrease serum concentrations of total thyroxine, without an accompanying change in thyroid stimulating hormone (TSH). This reduction in total thyroxine values is probably the result of reduced thyroxine binding to or displacement from transthyretin (TTR) due to the high binding affinity of tafamidis to the TTR thyroxine receptor. No corresponding clinical findings consistent with hypothyroidism have been observed.</p><p>&nbsp;</p><p>Biomarkers associated with heart failure (NT‑proBNP and Troponin I) favored VYNDAQEL over placebo.</p><p>&nbsp;</p><p><u>Cardiac Electrophysiology</u></p><p>At approximately 2.2 times the steady state peak plasma concentration (C<sub>max</sub>) at the recommended dose, tafamidis does not prolong the QTc interval to any clinically relevant extent.</p><p>&nbsp;</p><p><strong>CLINICAL STUDIES</strong></p><p>&nbsp;</p><p>Efficacy was demonstrated in a multicenter, international, randomized, double‑blind, placebo‑controlled study in 441 patients with wild type or hereditary ATTR‑CM (NCT01994889).</p><p>&nbsp;</p><p>Patients were randomized in a 1:2:2&nbsp;ratio to receive VYNDAQEL 20&nbsp;mg (n=88), VYNDAQEL 80&nbsp;mg (administered as four 20‑mg VYNDAQEL capsules) (n=176), or matching placebo (n=177) once daily for 30&nbsp;months, in addition to standard of care (e.g., diuretics). Treatment assignment was stratified by the presence or absence of a variant TTR genotype as well as baseline disease severity (NYHA Class). Transplant patients were excluded from this study. Table 1 describes the patient demographics and baseline characteristics.</p><p>&nbsp;</p><p><strong>Table 1: Patient Demographics and Baseline Characteristics </strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>Characteristic</strong></p></td><td style="vertical-align:top"><p><strong>Pooled Tafamidis</strong></p><p><strong>N=264</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>N=177</strong></p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p>Age &mdash; years</p></td></tr><tr><td style="vertical-align:top"><p>Mean (standard deviation)</p></td><td style="vertical-align:top"><p>74.5 (7.2)</p></td><td style="vertical-align:top"><p>74.1 (6.7)</p></td></tr><tr><td style="vertical-align:top"><p>Median (minimum, maximum)</p></td><td style="vertical-align:top"><p>75 (46, 88)</p></td><td style="vertical-align:top"><p>74 (51, 89)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Sex &mdash; number (%)</p></td></tr><tr><td style="vertical-align:top"><p>Male</p></td><td style="vertical-align:top"><p>241 (91.3)</p></td><td style="vertical-align:top"><p>157 (88.7)</p></td></tr><tr><td style="vertical-align:top"><p>Female</p></td><td style="vertical-align:top"><p>23 (8.7)</p></td><td style="vertical-align:top"><p>20 (11.3)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>TTR</em> Genotype &mdash; number (%)</p></td></tr><tr><td style="vertical-align:top"><p>ATTRm</p></td><td style="vertical-align:top"><p>63 (23.9)</p></td><td style="vertical-align:top"><p>43 (24.3)</p></td></tr><tr><td style="vertical-align:top"><p>ATTRwt</p></td><td style="vertical-align:top"><p>201 (76.1)</p></td><td style="vertical-align:top"><p>134 (75.7)</p></td></tr><tr><td style="vertical-align:top"><p>NYHA Class &mdash; number (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>NYHA Class I</p></td><td style="vertical-align:top"><p>24 (9.1)</p></td><td style="vertical-align:top"><p>13 (7.3)</p></td></tr><tr><td style="vertical-align:top"><p>NYHA Class II</p></td><td style="vertical-align:top"><p>162 (61.4)</p></td><td style="vertical-align:top"><p>101 (57.1)</p></td></tr><tr><td style="vertical-align:top"><p>NYHA Class III</p></td><td style="vertical-align:top"><p>78 (29.5)</p></td><td style="vertical-align:top"><p>63 (35.6)</p></td></tr></tbody></table><p>Abbreviations: ATTRm = variant transthyretin amyloid, ATTRwt = wild type transthyretin amyloid</p><p>&nbsp;</p><p>The primary analysis used a hierarchical combination applying the method of Finkelstein‑Schoenfeld (F‑S) to all‑cause mortality and frequency of cardiovascular‑related hospitalizations, which was defined as the number of times a subject was hospitalized (i.e., admitted to a hospital) for cardiovascular‑related morbidity. The method compared each patient to every other patient within each stratum in a pair‑wise manner that proceeded in a hierarchical fashion using all‑cause mortality followed by frequency of cardiovascular‑related hospitalizations when patients could not be differentiated based on mortality.</p><p>&nbsp;</p><p>This analysis demonstrated a significant reduction (p=0.0006) in all‑cause mortality and frequency of cardiovascular‑related hospitalizations in the pooled VYNDAQEL 20-mg and 80-mg groups versus placebo (Table 2).</p><p>&nbsp;</p><p><strong>Table 2:</strong> <strong>Primary Analysis Using Finkelstein‑Schoenfeld (F‑S) Method of All‑Cause Mortality and Frequency of Cardiovascular‑Related Hospitalizations </strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>Primary Analysis</strong></p></td><td style="vertical-align:top"><p><strong>Pooled VYNDAQEL</strong></p><p><strong>N=264</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>N=177</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Number (%) of Subjects Alive* at Month 30</p></td><td style="vertical-align:top"><p>186 (70.5)</p></td><td style="vertical-align:top"><p>101 (57.1)</p></td></tr><tr><td style="vertical-align:top"><p>Mean Number of Cardiovascular‑related Hospitalizations During 30&nbsp;months (per patient per year) Among Those Alive at Month&nbsp;30</p></td><td style="vertical-align:top"><p>0.297</p></td><td style="vertical-align:top"><p>0.455</p></td></tr><tr><td style="vertical-align:top"><p>p‑value from F‑S Method</p></td><td colspan="2" style="vertical-align:top"><p>0.0006</p></td></tr></tbody></table><p>* Heart transplantation and cardiac mechanical assist device implantation are considered indicators of approaching end stage. As such, these subjects are treated in the analysis as equivalent to death. Therefore, such subjects are not included in the count of &ldquo;Number of Subjects Alive at Month 30&rdquo; even if such subjects are alive based on 30 month vital status follow‑up assessment.</p><p>&nbsp;</p><p>Analysis of the individual components of the primary analysis (all‑cause mortality and cardiovascular‑related hospitalization) also demonstrated significant reductions for VYNDAQEL versus placebo.</p><p>&nbsp;</p><p>The hazard ratio from the all‑cause mortality Cox‑proportional hazard model for pooled VYNDAQEL versus placebo was 0.70&nbsp;(95%&nbsp;confidence interval [CI]&nbsp;0.51, 0.96), indicating a 30% relative reduction in the risk of death relative to the placebo group (p=0.026). Approximately 80% of total deaths were cardiovascular‑related in both treatment groups. A Kaplan‑Meier plot of time to event all‑cause mortality is presented in Figure&nbsp;1.</p><p>&nbsp;</p><p><strong>Figure 1: All‑Cause Mortality* </strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_29" o:spid="_x0000_s1028" type="#_x0000_t75"
 style='position:absolute;left:0;text-align:left;margin-left:66.3pt;
 margin-top:-275.15pt;width:348.5pt;height:285.5pt;z-index:251665408;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page'>
 <v:imagedata src="file:///C:/Users/bakhsm/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="465" height="381" src="file:///C:/Users/bakhsm/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" />&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>*Heart transplants and cardiac mechanical assist devices treated as death. Hazard ratio from Cox proportional hazards model with treatment, TTR genotype (variant and wild type), and NYHA baseline classification (NYHA Classes I and II combined and NYHA Class III) as factors.</p><p>&nbsp;</p><p>There were significantly fewer cardiovascular‑related hospitalizations with VYNDAQEL compared with placebo with a reduction in risk of 32% corresponding to a Relative Risk Ratio of 0.68 (Table 3).</p><p>&nbsp;</p><p><strong>Table 3: Cardiovascular‑Related Hospitalization Frequency </strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Pooled VYNDAQEL</strong></p><p><strong>N=264</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>N=177</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Total (%) Number of Subjects with Cardiovascular‑related Hospitalizations</p></td><td style="vertical-align:top"><p>138 (52.3)</p></td><td style="vertical-align:top"><p>107 (60.5)</p></td></tr><tr><td style="vertical-align:top"><p>Cardiovascular‑related Hospitalizations per Year*</p></td><td style="vertical-align:top"><p>0.48</p></td><td style="vertical-align:top"><p>0.70</p></td></tr><tr><td style="vertical-align:top"><p>Pooled VYNDAQEL vs Placebo Treatment Difference (Relative Risk Ratio)*</p></td><td colspan="2" style="vertical-align:top"><p>0.68</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>p‑value*</p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td></tr></tbody></table><p>*This analysis was based on a Poisson regression model with treatment, TTR genotype (variant and wild type), New York Heart Association (NYHA). Baseline classification (NYHA Classes I and II combined and NYHA Class III), treatment‑by‑TTR genotype interaction, and treatment‑by‑NYHA baseline classification interaction terms as factors.</p><p>&nbsp;</p><p>The treatment effects of VYNDAQEL on functional capacity and health status were assessed by the 6‑Minute Walk Test (6MWT) and the Kansas City Cardiomyopathy Questionnaire‑Overall Summary (KCCQ‑OS) score, respectively. A significant treatment effect favoring VYNDAQEL was first observed at Month 6 and remained consistent through Month 30 on both 6MWT distance and KCCQ‑OS score (Figure 2 and Table 4).</p><p>&nbsp;</p><p><strong>Figure 2:</strong> <strong>Change from Baseline to Month 30 in 6MWT Distance and KCCQ‑OS Score</strong></p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_3" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:502.5pt;
 height:233.25pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/bakhsm/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png"
  o:title=""/>
</v:shape><![endif]--><img width="670" height="311" src="file:///C:/Users/bakhsm/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png" /></p><p>Abbreviations: 6MWT=6‑Minute Walk Test, KCCQ-OS=Kansas City Cardiomyopathy Questionnaire-Overall Summary.</p><p>Panel A shows change from Baseline to Month 30 in pooled VYNDAQEL patients compared with placebo patients in 6MWT distance.</p><p>Panel B shows change from Baseline to Month 30 in pooled VYNDAQEL patients compared with placebo patients in KCCQ‑OS score.</p><p><strong>&nbsp;</strong></p><p>The Kansas City Cardiomyopathy Questionnaire‑Overall Summary (KCCQ‑OS) score is composed of four domains including Total Symptoms (Symptom Frequency and Symptom Burden), Physical Limitation, Quality of Life, and Social Limitation. The Overall Summary score and domain scores range from 0 to 100, with higher scores representing better health status. All four domains favored pooled VYNDAQEL compared to placebo at Month&nbsp;30, and demonstrated similar treatment effects to the KCCQ-OS score (Figure 2 and Table 4). The distribution for change from Baseline to Month 30 for KCCQ‑OS (Figure 3) shows that the proportion of patients with worse KCCQ‑OS scores was lower for the pooled VYNDAQEL‑treated group compared to placebo, and the proportion with improved scores was higher (Figure 3).</p><p>&nbsp;</p><p><strong>Figure 3: Histogram of Change from Baseline to Month 30 in KCCQ‑Overall Summary Score</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_31" o:spid="_x0000_s1027" type="#_x0000_t75" style='position:absolute;
 left:0;text-align:left;margin-left:84.15pt;margin-top:.05pt;width:314.2pt;
 height:245pt;z-index:251664384;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page'>
 <v:imagedata src="file:///C:/Users/bakhsm/AppData/Local/Temp/msohtmlclip1/01/clip_image004.png"
  o:title=""/>
 <w:wrap type="through"/>
</v:shape><![endif]--><img width="419" height="327" src="file:///C:/Users/bakhsm/AppData/Local/Temp/msohtmlclip1/01/clip_image005.png" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Abbreviation: KCCQ-OS=Kansas City Cardiomyopathy Questionnaire-Overall Summary.</p><p>&nbsp;</p><p><strong>Table 4: 6MWT Distance and KCCQ‑OS Scores </strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td rowspan="2" style="vertical-align:top"><p><strong>Endpoints</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Baseline Mean (SD)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Change from Baseline to Month&nbsp;30, LS Mean (SE)</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Treatment Difference from Placebo </strong></p><p><strong>LS Mean (95% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Pooled VYNDAQEL</strong></p><p><strong>N=264</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>N=177</strong></p></td><td style="vertical-align:top"><p><strong>Pooled VYNDAQEL </strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>&nbsp;</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>6MWT (meters)</strong></p></td><td style="vertical-align:top"><p>351</p><p>(121)</p></td><td style="vertical-align:top"><p>353</p><p>(126)</p></td><td style="vertical-align:top"><p>‑55</p><p>(5)</p></td><td style="vertical-align:top"><p>‑131</p><p>(10)</p></td><td style="vertical-align:top"><p>76</p><p>(58, 94)</p></td></tr><tr><td style="vertical-align:top"><p><strong>KCCQ‑OS </strong></p></td><td style="vertical-align:top"><p>67</p><p>(21)</p></td><td style="vertical-align:top"><p>66</p><p>(22)</p></td><td style="vertical-align:top"><p>‑7</p><p>(1)</p></td><td style="vertical-align:top"><p>‑21</p><p>(2)</p></td><td style="vertical-align:top"><p>14</p><p>(9, 18)</p></td></tr></tbody></table><p>Abbreviations: 6MWT&nbsp;=&nbsp;6‑Minute Walk Test; KCCQ‑OS&nbsp;=&nbsp;Kansas City Cardiomyopathy Questionnaire‑Overall Summary; SD&nbsp;=&nbsp;standard deviation; LS&nbsp;=&nbsp;least squares; SE&nbsp;=&nbsp;standard error; CI&nbsp;=&nbsp;confidence interval</p><p>&nbsp;</p><p>Results from the F‑S method represented by win ratio for the combined endpoint and its components (all‑cause mortality and frequency of CV‑related hospitalization) consistently favored VYNDAQEL versus placebo across all subgroups (wild type, variant and NYHA Class I &amp; II, and III), except for CV‑related hospitalization frequency in NYHA Class III (Figure 4). Win ratio is the number of pairs of VYNDAQEL‑treated patient &ldquo;wins&rdquo; divided by number of pairs of placebo patient &ldquo;wins.&rdquo; Analyses of 6MWT and KCCQ‑OS also favored VYNDAQEL relative to placebo within each subgroup.</p><p><strong>&nbsp;</strong></p><p><strong>Figure 4: Results by Subgroup, Dose, and Components of Primary Analysis</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_32" o:spid="_x0000_s1026"
 type="#_x0000_t75" style='position:absolute;margin-left:0;margin-top:-155.65pt;
 width:448pt;height:166pt;z-index:251666432;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:inside;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page'>
 <v:imagedata src="file:///C:/Users/bakhsm/AppData/Local/Temp/msohtmlclip1/01/clip_image006.png"
  o:title=""/>
</v:shape><![endif]--><img width="597" height="221" src="file:///C:/Users/bakhsm/AppData/Local/Temp/msohtmlclip1/01/clip_image007.png" />&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Abbreviations: ATTRm&nbsp;=&nbsp;variant transthyretin amyloid, ATTRwt&nbsp;=&nbsp;wild type transthyretin amyloid, F‑S&nbsp;=&nbsp;Finkelstein Schoenfeld, CI&nbsp;=&nbsp;Confidence Interval</p><p>*F‑S results presented using win ratio (based on all‑cause mortality and frequency of cardiovascular hospitalization)</p><p>Heart transplants and cardiac mechanical assist devices treated as death.</p><p>&nbsp;</p><p>Results of the primary analysis, 6MWT at Month&nbsp;30 and KCCQ‑OS at Month&nbsp;30 were statistically significant for both the 80‑mg and 20‑mg doses of VYNDAQEL vs. placebo, with similar results for both doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No clinically significant differences in steady&nbsp;state C<sub>max</sub> and area under the plasma concentration over time curve (AUC) of tafamidis were observed for VYNDAMAX 61‑mg capsule compared to VYNDAQEL administered as four 20‑mg capsules.</p><p>&nbsp;</p><p>Tafamidis exposure increases proportionally over single (up to 480 mg) or multiple (up to 80&nbsp;mg) (1 to 6 times the approved recommended dosage) once daily dosing.</p><p>&nbsp;</p><p>The apparent clearance were similar after single and repeated administration of VYNDAQEL 80&nbsp;mg.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>Median tafamidis peak concentrations occurred within 4 hours following dosing.</p><p>&nbsp;</p><p>Effect of Food</p><p>No clinically significant differences in the pharmacokinetics of tafamidis were observed following administration of a high fat, high calorie meal.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The apparent steady&nbsp;state volume of distribution of tafamidis melgumine is 16 liters and 18.5 liters of tafamidis. Plasma protein binding of tafamidis is &gt;99% in vitro. Tafamidis primarily binds to TTR.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The mean half‑life of tafamidis is approximately 49&nbsp;hours. The apparent oral clearance of tafamidis meglumine is 0.228 L/h (0.263&nbsp;L/h for tafamidis). The degree of drug accumulation at steady&nbsp;state after repeated tafamidis daily dosing is approximately 2.5‑fold greater than that observed after a single&nbsp;dose.</p><p><u>&nbsp;</u></p><p>Metabolism</p><p>The metabolism of tafamidis has not been fully characterized. However, glucuronidation has been observed.&nbsp;</p><p>&nbsp;</p><p>Excretion</p><p>After a single oral dose of tafamidis meglumine 20 mg, approximately 59% of the dose was recovered in feces (mostly as the unchanged drug) and approximately 22% of the dose was recovered in urine (mostly as the glucuronide metabolite).</p><p><u>&nbsp;</u></p><p><u>Specific Populations</u></p><p>No clinically significant differences in the pharmacokinetics of tafamidis were observed based on age, race/ethnicity (Caucasian and Japanese) or renal impairment.</p><p>&nbsp;</p><p>Patients with Hepatic Impairment</p><p>Patients with moderate hepatic impairment (Child‑Pugh Score of 7 to 9) had decreased systemic exposure (approximately 40%) and increased clearance (approximately 68%) of tafamidis compared to healthy subjects. As TTR levels are lower in subjects with moderate hepatic impairment than in healthy subjects, the exposure of tafamidis relative to the amount of TTR is sufficient to maintain stabilization of the TTR tetramer in these patients. No clinically significant differences in the pharmacokinetics of tafamidis were observed in patients with mild hepatic impairment (Child Pugh Score of 5 to 6) compared to healthy subjects. The effect of severe hepatic impairment on tafamidis is unknown.</p><p><u>&nbsp;</u></p><p><u>Drug Interaction Studies</u></p><p>Clinical Studies</p><p>CYP3A4 substrates: No clinically significant differences in the pharmacokinetics of midazolam (a CYP3A4 substrate) or on the formation of its active metabolite (1‑hydroxymidazolam) were observed when a single 7.5-mg dose of midazolam was administered prior to and after a 14‑day regimen of VYNDAQEL 20‑mg once daily.</p><p>&nbsp;</p><p>BCRP substrates: Tafamidis inhibits breast cancer resistant protein (BCRP). In a clinical study in healthy participants, AUC<sub>inf</sub> and C<sub>max</sub> of the BCRP substrate rosuvastatin increased by 96.75% and 85.59%, respectively following multiple doses of VYNDAMAX 61 mg daily dosing.</p><p>&nbsp;</p><p>In Vitro Studies</p><p><u>Cytochrome P450 Enzymes</u>: Tafamidis induces CYP2B6 and CYP3A4 and does not induce CYP1A2. Tafamidis does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4/5 or CYP2D6.</p><p>&nbsp;</p><p><u>UDP glucuronosyltransferase (UGT)</u>: Tafamidis inhibits intestinal activities of UGT1A1 but neither induces nor inhibits other UDP glucuronosyltransferase (UGT) systemically.</p><p>&nbsp;</p><p><u>Transporter Systems</u>: In vitro studies and model predictions show that tafamidis has a low potential to inhibit organic anion transporters OAT1 and OAT3 at clinically relevant concentrations. Tafamidis did not show a potential to inhibit Multi‑Drug Resistant Protein (MDR1) (also known as P‑glycoprotein; P‑gp), organic cation transporter OCT2, multidrug and toxin extrusion transporters MATE1 and MATE2K and, organic anion transporting polypeptide OATP1B1 and OATP1B3.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Carcinogenesis, Mutagenesis, Impairment of Fertility</strong></p><p><u>Carcinogenesis</u></p><p>There was no evidence of an increased incidence of neoplasia in the transgenic (Tg)‑rasH2 mouse following repeated daily administration for 26 weeks at daily doses of 0, 10, 30 or 90 mg/kg. There was no evidence of increased incidence of neoplasia in a 2‑year carcinogenicity study in rats at exposures up to 18&nbsp;times the AUC at the MRHD.</p><p>&nbsp;</p><p><u>Mutagenesis</u></p><p>There was no evidence of mutagenicity or clastogenicity in vitro, and an in vivo rat micronucleus study was negative.</p><p>&nbsp;</p><p><u>Impairment of Fertility</u></p><p>There were no effects of tafamidis meglumine on fertility, reproductive performance, or mating behavior in the rat at any dose. Rats were dosed daily (0, 5, 15, and 30&nbsp;mg/kg/day) prior to cohabitation (for at least 15 days for females and 28 days for males), throughout the cohabitation period to the day prior to termination of males and through to implantation of females (Gestation Day 7). No adverse effects were noted on male and female rats in toxicity, fertility, and mating behavior at any dose. The paternal and maternal no observed adverse effect level for reproductive toxicity of tafamidis meglumine is 30&nbsp;mg/kg/day, approximately 4 times the MRHD on a mg/m<sup>2</sup> basis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Polyethylene Glycol 400<br />Polysorbate 20<br />Povidone<br />Butylated Hydroxytoluene<br /><br />Gelatin Shell Ingredients:<br />Gelatin<br />Sorbitol Special-Glycerin Blend<br />Iron Oxide, Red<br /><br />Gelatin Shell Printing Ingredients:<br />Ink, White Opacode</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.

Do not use VYNDAMAX after the expiry date which is stated on the carton / Blister label after EXP:. The expiry date refers to the last day of that month.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the sight and reach of children.</p><p><strong>&nbsp;</strong></p><p>Don&#39;t store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carton of 3 Aluminum foil blister cards. Each blister card contains 10 capsules (30 capsules total).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p><p><br />Any unused medicinal product or waste material should be disposed of in accordance with local requirements.<br /><br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pfizer Inc.
66 Hudson Boulevard East, New York, NY 10001, USA

MANUFACUTRED BY
Catalent Pharma Solutions, LLC, 
2725 Scherer Drive North, 
Saint Petersburg, FL, 
33716, United States

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>